Recently, a compensatory activation of others ERBB family receptors was observed in GBM-SCs following EGFR abrogation, thus raising the possibility that efficient anti-EGFR therapy requires the co-targeting of multiple family members (Clark et al., 2012). Here, EGFR is linked to glioblastoma.